Published in Metab Brain Dis on December 01, 2005
Cellular multitasking: the dual role of human Cu-ATPases in cofactor delivery and intracellular copper balance. Arch Biochem Biophys (2008) 1.33
Manganese-induced trafficking and turnover of the cis-Golgi glycoprotein GPP130. Mol Biol Cell (2010) 1.16
Mechanisms of copper ion mediated Huntington's disease progression. PLoS One (2007) 1.08
Manganese homeostasis in the nervous system. J Neurochem (2015) 0.98
Copper redistribution in Atox1-deficient mouse fibroblast cells. J Biol Inorg Chem (2009) 0.97
Systemic abnormalities in liver disease. World J Gastroenterol (2009) 0.78
Simultaneous monitoring of cerebral metal accumulation in an experimental model of Wilson's disease by laser ablation inductively coupled plasma mass spectrometry. BMC Neurosci (2014) 0.76
Laser ablation inductively coupled plasma mass spectrometry imaging of metals in experimental and clinical Wilson's disease. J Cell Mol Med (2015) 0.75
Movement disorder due to aceruloplasminemia and incorrect diagnosis of hereditary hemochromatosis. J Neurol (2007) 0.75
Evaluation of oxidative events and copper accumulatıon in oral tissues of patients wıth Wilson's disease: three case report. Int J Clin Exp Pathol (2015) 0.75
Copper Corrosion and Biocorrosion Events in Premise Plumbing. Materials (Basel) (2017) 0.75
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med (2010) 8.58
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol (2005) 3.27
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (2014) 2.56
Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology (2003) 2.56
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology (2003) 2.54
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Obesity is associated with increased morbidity but not mortality in critically ill patients. Intensive Care Med (2008) 2.27
World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol (2014) 2.17
Accuracy and reliability of a subcutaneous continuous glucose-monitoring system in critically ill patients. Crit Care Med (2011) 2.10
Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. J Hepatol (2013) 2.04
Real-time continuous glucose monitoring in critically ill patients: a prospective randomized trial. Diabetes Care (2009) 1.97
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology (2010) 1.80
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology (2012) 1.76
Dynamic coinfection with multiple viral subtypes in acute hepatitis C. J Infect Dis (2010) 1.75
Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2010) 1.73
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2011) 1.70
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. J Hepatol (2012) 1.68
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut (2012) 1.63
Impaired subcortical and cortical sensory evoked potential pathways in septic patients. Crit Care Med (2002) 1.63
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology (2011) 1.62
Impact of shock requiring norepinephrine on the accuracy and reliability of subcutaneous continuous glucose monitoring. Intensive Care Med (2009) 1.61
Novel mutations of the ATP7B gene among 109 Hungarian patients with Wilson's disease. Eur J Gastroenterol Hepatol (2007) 1.57
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin. Hepatology (2011) 1.55
A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol (2010) 1.54
Outcome of elderly patients with circulatory failure. Intensive Care Med (2013) 1.53
World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis (2010) 1.52
Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis. Clin Infect Dis (2004) 1.52
Improvement of glucose control in the intensive care unit: an interdisciplinary collaboration study. Am J Crit Care (2008) 1.49
Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int (2009) 1.48
Diagnosis of minimal hepatic encephalopathy: still a challenge. Gut (2013) 1.46
Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med (2003) 1.44
Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson's disease in children. J Hepatol (2007) 1.44
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. Liver Int (2014) 1.42
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol (2010) 1.38
Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology (2010) 1.34
Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients. Intensive Care Med (2009) 1.31
Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology (2011) 1.30
Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol (2002) 1.28
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology (2013) 1.28
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Hepatology (2013) 1.26
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology (2010) 1.21
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol (2005) 1.19
Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. Surg Endosc (2013) 1.17
Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol (2002) 1.17
Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol (2004) 1.16
Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology (2002) 1.14
Glycemic variability and glucose complexity in critically ill patients: a retrospective analysis of continuous glucose monitoring data. Crit Care (2012) 1.13
Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. J Hepatol (2011) 1.12
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol (2012) 1.10
Impact of hypoxic hepatitis on mortality in the intensive care unit. Intensive Care Med (2011) 1.10
Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol (2012) 1.08
Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med (2005) 1.07
Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology (2006) 1.05
Common mutations of ATP7B in Wilson disease patients from Hungary. Am J Med Genet (2002) 1.05
Silymarin for HCV infection. Antivir Ther (2012) 1.04
Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol (2013) 1.02
Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology (2013) 1.02
Evolution of Crohn's disease-associated Nod2 mutations. Immunogenetics (2008) 1.01
Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J Hepatol (2010) 1.00
Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology (2011) 1.00
Infliximab: lack of efficacy on perforating complications in Crohn's disease. Inflamm Bowel Dis (2004) 0.99
Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol (2006) 0.99
Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int (2010) 0.99
Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C. Am J Gastroenterol (2006) 0.98
Hepatocyte GP73 expression in Wilson disease. J Hepatol (2009) 0.96
Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr (2009) 0.94
Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy. J Hepatol (2010) 0.93
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection. Gastroenterology (2013) 0.92
Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy. Eur J Radiol (2009) 0.91
Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol (2003) 0.91
Cognitive deficit after aortic valve replacement. Ann Thorac Surg (2002) 0.91
Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. Antivir Ther (2011) 0.91
Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol (2006) 0.91
Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus. Clin Infect Dis (2012) 0.90
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol (2011) 0.90
Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antivir Ther (2008) 0.90
Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol (2012) 0.89
Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection. AIDS (2005) 0.89
Plummer-Vinson syndrome associated with celiac disease and complicated by postcricoid carcinoma and carcinoma of the tongue. Am J Gastroenterol (2003) 0.87
IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur J Clin Invest (2011) 0.86
Clinical impact of arterial ammonia levels in ICU patients with different liver diseases. Intensive Care Med (2013) 0.86
Truncating mutations in the Wilson disease gene ATP7B are associated with very low serum ceruloplasmin oxidase activity and an early onset of Wilson disease. BMC Gastroenterol (2010) 0.86
Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol (2004) 0.86
Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver Int (2014) 0.86
Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients. BMC Cancer (2007) 0.85
Neurophysiological evidence of cognitive impairment in patients without hepatic encephalopathy after transjugular intrahepatic portosystemic shunts. Am J Gastroenterol (2002) 0.85
Platelet aggregation and blood rheology in severe sepsis/septic shock: relation to the Sepsis-related Organ Failure Assessment (SOFA) score. Clin Hemorheol Microcirc (2004) 0.85
Copper toxicosis gene MURR1 is not changed in Wilson disease patients with normal blood ceruloplasmin levels. World J Gastroenterol (2006) 0.85
Genetic analysis of BIRC4/XIAP as a putative modifier gene of Wilson disease. J Inherit Metab Dis (2010) 0.84
Jejunal tube placement in critically ill patients: A prospective, randomized trial comparing the endoscopic technique with the electromagnetically visualized method. Crit Care Med (2011) 0.84
Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. J Inherit Metab Dis (2011) 0.83
Comparison of alcohol-dependent patients at a gastroenterological and a psychiatric ward according to the Lesch alcoholism typology: implications for treatment. Alcohol Alcohol (2010) 0.83